Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lindberg, C.
Right arrow Articles by Oldfors, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lindberg, C.
Right arrow Articles by Oldfors, A.
Related Collections
Right arrow Autoimmune diseases
Right arrow Muscle disease
Right arrow All Clinical trials
Right arrow Clinical trials Observational study (Cohort, Case control)

Neurology 2003;61:260-262
© 2003 American Academy of Neurology
Brief Communications

Anti–T-lymphocyte globulin treatment in inclusion body myositis

A randomized pilot study

C. Lindberg, MD PhD, E. Trysberg, MD, A. Tarkowski, MD PhD and A. Oldfors, MD PhD

From the Departments of Neurology (Dr. Lindberg), Rheumatology (Drs. Trysberg and Tarkowski), and Pathology (Dr. Oldfors), Sahlgrenska University Hospital, Sahlgrenska NeuroMuscular Center, Gothenburg, Sweden.

Address correspondence and reprint requests to Dr. Christopher Lindberg, NeuroMuscular Center, Department of Neurology, Sahlgrenska University Hospital/Molndal, S-431 80 Molndal, Sweden; e-mail: christopher.lindberg{at}vgregion.se

The authors performed an open, randomized trial in patients with inclusion body myositis comparing 1) 12-month treatment with oral methotrexate 7.5 mg/week alone (MTX group) with 2) 12-month MTX treatment preceded by 7 days of IV anti–T-lymphocyte immunoglobulin treatment (ATG group). Eleven patients were randomized; 10 patients completed 12 months follow-up. Myometry showed that patients in the ATG group (n = 6) increased in mean muscle strength by 1.4% compared with the MTX group (n = 5), whose muscle strength decreased by 11.1% (p = 0.021).




This article has been cited by other articles:


Home page
 Arch NeurolHome page
J. C. Novak, A. E. Lovett-Racke, and M. K. Racke
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol, September 1, 2008; 65(9): 1162 - 1165.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S. A. Greenberg
Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications
Neurology, November 20, 2007; 69(21): 2008 - 2019.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
A C Cordeiro and D A Isenberg
Treatment of inflammatory myopathies.
Postgrad. Med. J., July 1, 2006; 82(969): 417 - 424.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. C. Dalakas
Inflammatory, immune, and viral aspects of inclusion-body myositis
Neurology, January 24, 2006; 66(1_suppl_1): S33 - S38.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
R. C. Griggs
The current status of treatment for inclusion-body myositis
Neurology, January 24, 2006; 66(1_suppl_1): S30 - S32.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
J. Schmidt, G. Rakocevic, R. Raju, and M. C. Dalakas
Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity
Brain, May 1, 2004; 127(5): 1182 - 1190.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by AAN Enterprises, Inc.